5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.

George J Dover, S. H. Charache, S. H. Boyer, C. C. Talbot, Kirby D. Smith

Research output: Contribution to journalArticle

Abstract

5-Azacytidine, given to one sickle cell patient as 9 doses of 30 mg/m2 each at intervals of 8 hr, rapidly increased the number of red cells containing HbF (F cells), decreased the amount of HbS in F cells, and decreased the MCHC of F cells. Although a significant rise in the peripheral blood hemoglobin from 8 gm/dl to 10-12 gm/dl was obtained, painful vaso-occlusive crises continued to occur. Therapy was associated with no marrow toxicity, although erythroblastosis appeared after each course of therapy. Increased HbF production was associated with demethylation of two restriction enzyme sites 5' to the two gamma-globin genes. Five other restriction sites around the gamma-globin genes were unchanged. 5-Azacytidine is considered potentially mutagenic and carcinogenic in man and, therefore, further experimental treatment should be limited only to severely affected sickle cell patients.

Original languageEnglish (US)
Pages (from-to)475-488
Number of pages14
JournalProgress in Clinical and Biological Research
Volume134
StatePublished - 1983
Externally publishedYes

Fingerprint

Azacitidine
Fetal Hemoglobin
Sickle Cell Anemia
gamma-Globins
Genes
Hemoglobins
Therapeutics
Cell Count
Bone Marrow
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease. / Dover, George J; Charache, S. H.; Boyer, S. H.; Talbot, C. C.; Smith, Kirby D.

In: Progress in Clinical and Biological Research, Vol. 134, 1983, p. 475-488.

Research output: Contribution to journalArticle

@article{7d14cfb091dc42e3a22634fbce1dcb15,
title = "5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.",
abstract = "5-Azacytidine, given to one sickle cell patient as 9 doses of 30 mg/m2 each at intervals of 8 hr, rapidly increased the number of red cells containing HbF (F cells), decreased the amount of HbS in F cells, and decreased the MCHC of F cells. Although a significant rise in the peripheral blood hemoglobin from 8 gm/dl to 10-12 gm/dl was obtained, painful vaso-occlusive crises continued to occur. Therapy was associated with no marrow toxicity, although erythroblastosis appeared after each course of therapy. Increased HbF production was associated with demethylation of two restriction enzyme sites 5' to the two gamma-globin genes. Five other restriction sites around the gamma-globin genes were unchanged. 5-Azacytidine is considered potentially mutagenic and carcinogenic in man and, therefore, further experimental treatment should be limited only to severely affected sickle cell patients.",
author = "Dover, {George J} and Charache, {S. H.} and Boyer, {S. H.} and Talbot, {C. C.} and Smith, {Kirby D.}",
year = "1983",
language = "English (US)",
volume = "134",
pages = "475--488",
journal = "Progress in Clinical and Biological Research",
issn = "0361-7742",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.

AU - Dover, George J

AU - Charache, S. H.

AU - Boyer, S. H.

AU - Talbot, C. C.

AU - Smith, Kirby D.

PY - 1983

Y1 - 1983

N2 - 5-Azacytidine, given to one sickle cell patient as 9 doses of 30 mg/m2 each at intervals of 8 hr, rapidly increased the number of red cells containing HbF (F cells), decreased the amount of HbS in F cells, and decreased the MCHC of F cells. Although a significant rise in the peripheral blood hemoglobin from 8 gm/dl to 10-12 gm/dl was obtained, painful vaso-occlusive crises continued to occur. Therapy was associated with no marrow toxicity, although erythroblastosis appeared after each course of therapy. Increased HbF production was associated with demethylation of two restriction enzyme sites 5' to the two gamma-globin genes. Five other restriction sites around the gamma-globin genes were unchanged. 5-Azacytidine is considered potentially mutagenic and carcinogenic in man and, therefore, further experimental treatment should be limited only to severely affected sickle cell patients.

AB - 5-Azacytidine, given to one sickle cell patient as 9 doses of 30 mg/m2 each at intervals of 8 hr, rapidly increased the number of red cells containing HbF (F cells), decreased the amount of HbS in F cells, and decreased the MCHC of F cells. Although a significant rise in the peripheral blood hemoglobin from 8 gm/dl to 10-12 gm/dl was obtained, painful vaso-occlusive crises continued to occur. Therapy was associated with no marrow toxicity, although erythroblastosis appeared after each course of therapy. Increased HbF production was associated with demethylation of two restriction enzyme sites 5' to the two gamma-globin genes. Five other restriction sites around the gamma-globin genes were unchanged. 5-Azacytidine is considered potentially mutagenic and carcinogenic in man and, therefore, further experimental treatment should be limited only to severely affected sickle cell patients.

UR - http://www.scopus.com/inward/record.url?scp=0021012176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021012176&partnerID=8YFLogxK

M3 - Article

C2 - 6198661

AN - SCOPUS:0021012176

VL - 134

SP - 475

EP - 488

JO - Progress in Clinical and Biological Research

JF - Progress in Clinical and Biological Research

SN - 0361-7742

ER -